Actuate Therapeutics Q2 FY26 net loss narrows to $4.87 million; operating loss improves to $4.91 million
ACTU•Q2 loss narrows as expenses fall
- Actuate Therapeutics posted a Q2 net loss of $4.87 million, narrowing from $5.95 million a year earlier.
- Operating loss improved to $4.91 million as operating expenses fell 17.8% to $4.91 million versus the prior-year quarter.
- R&D spending dropped 25.2% to $2.07 million on lower external clinical study costs tied to fewer patients in Actuate-1801 Part 3B.
- G&A expense declined 11.4% to $2.84 million, mainly on lower personnel-related costs, partly offset by higher investor and public relations fees.
- Cash and cash equivalents totaled $4.43 million at June 30, 2026; the company said it expects funding to last beyond September 2026 only with new capital.
